Larson Financial Group’s Soleno Therapeutics SLNO Stock Holding History

Larson Financial Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-230	Closed	-$7.7K	–	3912
2026 Q1	$7.7K	Buy	230 +60	+35%	+$2.35K	﹤0.01%	2387
2025 Q4	$7.87K	Buy	170 +55	+48%	+$3.02K	﹤0.01%	2252
2025 Q3	$7.77K	Buy	115 +40	+53%	+$2.97K	﹤0.01%	2149
2025 Q2	$6.28K	Buy	+75	New	+$5.61K	﹤0.01%	1999

Larson Financial Group's SLNO Position: Q2 2026 in Review

Larson Financial Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 230 shares — an estimated $7.7K sold.

Larson Financial Group first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $7.87K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Larson Financial Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Larson Financial Group sold 230 Soleno Therapeutics shares in Q2 2026, an estimated $7.7K.
Larson Financial Group first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
Larson Financial Group's Soleno Therapeutics position peaked at $7.87K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.